Effects of injectable or implantable progestin-only contraceptives on insulin-glucose metabolism and diabetes risk

Diabetes Care

Volumn 26, Issue 1, 2003, Pages 216-225

  Kahn, Henry S ^a   Curtis, Kathryn M ^a   Marchbanks, Polly A ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; ELCOMETRINE; ETONOGESTREL; GESTAGEN; GLUCOSE; INSULIN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NOMEGESTROL;

ADULT; CONTRACEPTION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG FORMULATION; DRUG IMPLANT; FEMALE; GLUCOSE METABOLISM; HORMONAL CONTRACEPTION; HUMAN; INJECTION; INTRAVENOUS GLUCOSE TOLERANCE TEST; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PREGNANCY DIABETES MELLITUS; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

CONTRACEPTIVE AGENTS, FEMALE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE; HUMANS; INCIDENCE; INSULIN; LEVONORGESTREL; MEDROXYPROGESTERONE 17-ACETATE; RISK FACTORS;

EID: 0042671315     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.1.216     Document Type: Review

References (68)

1. Fagot-Campagna A, Pettitt DJ, Engelgau MM, Burrows NR, Geiss LS, Valdez R, Beckles GL, Saaddine J, Gregg EW, Williamson DF, Narayan KM: Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr 136:664-672, 2000
2. Ferrara A, Quesenberry CP, Riley C, Hedderson MM, Kahn HS: Changes in prevalence of gestational diabetes mellitus (GDM): Northern California, 1991-1999 (Abstract). Diabetes 50 (Suppl. 2):A5, 2001
3. Kaunitz AM: Injectable long-acting contraceptives. Clin Obstet Gynecol 44:73-91, 2001
4. Croxatto HB: Progestin implants. Steroids 65:681-685, 2000
5. Hatcher R, Trussell J, Stewart F, Cates W, Stewart G, Guest F, Kowal D: Contraceptive Technology. 17th Ed. New York, Ardent Media, 1998
6. World Health Organization: Improving access to quality care in family planning. Medical eligibility criteria for contraceptive use, 2000 (article online). Available from http://www.who.int/reproductivehealth/publications/RHR_00_2_medical_ eligibility_criteria_secondedition/index.htm. Accessed 15 March 2002
7. American College of Obstetricians and Gynecologists: The Use of Hormonal Contraception in Women with Coexisting Medical Conditions. Washington, DC, American College of Obstetricians and Gynecologists, 2000 (Report no. 18)
8. American Diabetes Association: Preconception care of women with diabetes. Diabetes Care 25 (Suppl. 1):S82-S89, 2002
9. Kjos SL, Peters RK, Xiang A, Schaefer U, Buchanan TA: Hormonal choices after gestational diabetes: subsequent pregnancy, contraception, and hormone replacement, Diabetes Care 21 (Suppl. 2): B50-B57, 1998
10. Kim C, Seidel KW, Begier EA, Kwok YS: Diabetes and depot medroxyprogesterone contraception in Navajo women. Arch Intern Med 161:1766-1771, 2001
11. International Collaborative Post-Marketing Surveillance of Norplant: Post-marketing surveillance of Norplant contraceptive implants. II. Non-reproductive health Contraception 63:187-209, 2001
12. Gershberg H, Zorrilla E, Hernandez A, Hulse M: Effects of medroxyprogesterone acetate on serum insulin and growth hormone levels in diabetics and potential diabetics. Obstet Gynecol 33:383-389, 1969
13. Spellacy WN, McLeod AG, Buhi WC, Birk SA: The effects of medroxyprogesterone acetate on carbohydrate metabolism: measurements of glucose, insulin, and growth hormone after twelve months' use. Fertil Steril 23:239-244, 1972
14. Vermeulen A, Thiery M: Hormonal contraceptives and carbohydrate tolerance. II. Influence of medroxyprogesterone acetate and chronic oral contraceptives. Diabetologia 10:253-259, 1974
15. Tuttle S, Turkington VE: Effects of medroxyprogesterone acetate on carbohydrate metabolism. Obstet Gynecol 43:685-692, 1974
16. Liew DF, Ng CS, Yong YM, Ratnam SS: Long-term effects of Depo-Provera on carbohydrate and lipid metabolism. Contraception 31:51-64, 1985
17. Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D: Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study. Int J Gynaecol Obstet 24:291-296, 1986
18. Fahmy K, Abdel-Razik M, Shaaraway M, al-Kholy G, Saad S, Wagdi A, al-Azzony M: Effect of long-acting progestagen-only injectable contraceptives on carbohydrate metabolism and its hormonal profile. Contraception 44:419-430, 1991
19. Griffin M, Heaton DA, McEwan JA: Long-term use of an injectable contraceptive: effect of depot-norethisterone oenanthate on carbohydrate metabolism. Contraception 37:53-60, 1988
20. Tankeyoon M, Dusitsin N, Poshyachinda V, Larsson-Cohn U: A study of glucose tolerance, serum transaminase and lipids in women using depot-medroxyprogesterone acetate and a combination-type oral contraceptive. Contraception 14:199-214, 1976
21. Amatayakul K, Sivassomboon B, Singkamani R: Effects of medroxyprogesterone acetate on serum lipids, protein, glucose tolerance and liver function in Thai women. Contraception 21:283-297, 1980
22. Amatayakul K, Suriyanon V: The effects of long-acting injectable contraceptives on carbohydrate metabolism. Int J Gynaecol Obstet 23:361-368, 1985
23. Konje JC, Otolorin EO, Ladipo OA: Changes in carbohydrate metabolism during 30 months on Norplant. Contraception 44:163-172, 1991
24. Konje JC, Otolorin EO, Ladipo OA: The effect of continuous subdermal levonorgestrel (Norplant) on carbohydrate metabolism. Am J Obstet Gynecol 166:15-19, 1992
25. Konje JC, Odukoya OA, Otolorin EO, Ewings PD, Ladipo OA: Carbohydrate metabolism before and after Norplant removal. Contraception 46:61-69, 1992
26. Biswas A, Viegas OA, Coeling Bennink HJ, Korver T, Ratnam SS: Implanon contraceptive implants: effects on carbohydrate metabolism. Contraception 63:137-141, 2001
27. Shamma FN, Rossi G, HajHassan L, Penzias AS, Connoly-Diamond M, Jones E, Diamond MP: The effect of Norplant on glucose metabolism under hyperglycemic hyperinsulinemic conditions. Fertil Steril 63:767-772, 1995
28. Abma JC, Chandra A, Mosher WD, Peterson LS, Piccinino LJ: Fertility, family planning, and women's health: new data from the 1995 National Survey of Family Growth. Vital Health Stat 23:1-114, 1997
29. Trussell J, Vaughan B: Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plann Perspect 31:64-72, 93, 1999
30. Berenson AB, Wiemann CM, McCombs SL, Somma-Garcia A: The rise and fall of levonorgestrel implants: 1992-1996. Obstet Gynecol 92:790-794, 1998
31. de Vane PJ (Wyeth-Ayerst Pharmaceuticals): Letter to Norplant Providers (10 August). Philadelphia, PA, Wyeth-Ayerst Pharmaceuticals 2000
32. Pinkston Koenigs LM, Miller NH: The contraceptive use of Depo-Provera in U.S. adolescents. J Adolesc Health 16:347-349, 1995
33. Alan Guttmacher Institute: Family Planning Annual Report: 2000 Summary. New York, 2001
34. Margulies R, Miller L: Increased depot medroxyprogesterone acetate use increases family planning program pharmaceutical supply costs. Contraception 63:147-149, 2001
35. Piccinino LJ, Mosher WD: Trends in contraceptive use in the United States: 1982-1995. Fam Plann Perspect 30:4-10, 46, 1998
36. Dinerman LM, Wilson MD, Duggan AK, Joffe A: Outcomes of adolescents using levonorgestrel implants vs oral contraceptives or other contraceptive methods. Arch Pediatr Adolesc Med 149:967-972, 1995
37. O'Dell CM, Forke CM, Polaneczky MM, Sondheimer SJ, Slap GB: Depot medroxyprogesterone acetate or oral contraception in postpartum adolescents. Obstet Gynecol 91:609-614, 1998
38. Polaneczky M, Slap G, Forke C, Rappaport A, Sondheimer S: The use of levonorgestrel implants (Norplant) for contraception in adolescent mothers. N Engl J Med 331:1201-1206, 1994
39. Berenson AB, Wiemann CM: Contraceptive use among adolescent mothers at 6 months postpartum. Obstet Gynecol 89:999-1005, 1997
40. Bergman RN, Ader M: Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 11:351-356, 2000
41. Pouliot MC, Despres JP, Nadeau A, Tremblay A, Moorjani S, Lupien PJ, Theriault G, Bouchard C: Associations between regional body fat distribution, fasting plasma free fatty acid levels and glucose tolerance in premenopausal women. Int J Obes 14:293-302, 1990
42. Harper MA, Meis PJ, Steele L: A prospective study of insulin sensitivity and glucose metabolism in women using a continuous subdermal levonorgestrel implant system. J Soc Gynecol Investig 4:86-89, 1997
43. Pratley RE, Weyer C: The role of impaired early insulin secretion in the pathogenesis of type 11 diabetes mellitus. Diabetologia 44:929-945, 2001
44. Duckworth WC, Bennett RG, Hamel FG: Insulin degradation: progress and potential. Endocr Rev 19:608-624, 1998
45. Mykkanen L, Zaccaro DJ, Hales CN, Festa A, Haffner SM: The relation of proinsulin and insulin to insulin sensitivity and acute insulin response in subjects with newly diagnosed type II diabetes: the Insulin Resistance Atherosclerosis Study. Diabetologia 42:1060-1066, 1999
46. Westhoff C: Depot medroxyprogesterone acetate contraception: metabolic parameters and mood changes. J Reprod Med 41 (Suppl. 5):401-406, 1996
47. Risser WL, Gefter LR, Barratt MS, Risser JM: Weight change in adolescents who used hormonal contraception. J Adolesc Health 24:433-436, 1999
48. Espey E, Steinhart J, Ogbum T, Qualls C: Depo-provera associated with weight gain in Navajo women. Contraception 62:55-58, 2000
49. Amatayakul K, Sivasomboon B, Thanangkul O: A study of the mechanism of weight gain in medroxyprogesterone acetate users. Contraception 22:605-622, 1980
50. Sangi-Haghpeykar H, Poindexter AN 3rd, Bateman L, Ditmore JR: Experiences of injectable contraceptive users in an urban setting. Obstet Gynecol 88:227-233, 1996
51. Sivin I, Mishell DR Jr, Darney P, Wan L, Christ M: Levonorgestrel capsule implants in the United States: a 5-year study. Obstet Gynecol 92:337-344, 1998
52. Kahn HS, Williamson DF, Stevens JA: Race and weight change in US women: the roles of socioeconomic and marital status. Am J Public Health 81:319-323, 1991
53. Kritz-Silverstein D, Barrett-Connor E, Wingard DL, Friedlander NJ: Relation of pregnancy history to insulin levels in older, nondiabetic women. Am J Epidemiol 140:375-382, 1994
54. Boyko EJ, Alderman BW, Keane EM, Baron AE: Effects of childbearing on glucose tolerance and NIDDM prevalence. Diabetes Care 13:848-854, 1990
55. Beral V: Long term effects of childbearing on health. J Epidemiol Community Health 39:343-346, 1985
56. Peters RK, Kjos SL, Xiang A, Buchanan TA: Long-term diabetogenic effect of single pregnancy in women with previous gestational diabetes mellitus. Lancet 347:227-230, 1996
57. Kjos SL, Peters RK, Xiang A, Thomas D, Schaefer U, Buchanan TA: Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA 280:533-538, 1998
58. Flegal KM, Troiano RP: Changes in the distribution of body mass index of adults and children in the US population. Int J Obes Relat Metab Disord 24:807-818, 2000
59. Gordon-Larsen P, McMurray RG, Popkin BM: Adolescent physical activity and inactivity vary by ethnicity: the National Longitudinal Study of Adolescent Health. J Pediatr 135:301-306, 1999
60. Morgenstern H: Ecologic studies. In Modern Epidemiology. 2nd ed. Rothman K, Greenland S, Eds. Philadelphia, Lippincott, 1998, p. 459-480
61. Dorflinger LJ: Metabolic effects of implantable steroid contraceptives for women. Contraception 65:47-62, 2002
62. Diab KM, Zaki MM: Contraception in diabetic women: comparative metabolic study of Norplant, depot medroxyprogesterone acetate, low dose oral contraceptive pill and CuT380A. J Obstet Gynaecol Res 26:17-26, 2000
63. Dhall K, Kumar M, Rastogi GK, Devi PK: Short-term effects of norethisterone oenanthate and medroxyprogesterone acetate on glucose, insulin, growth hormone, and lipids. Fertil Steril 28:156-158, 1977
64. Andino N: Phase I clinical trial of two contraceptive preparations. Norethisterone enanthate (NEN) and norethisterone acetate (NET). Contraception 23:141-155, 1981
65. Lithell H, Weiner E, Vessby B, Johansson ED: Effects of continuous levonorgestrel treatment (subcutaneous capsules) on the lipoprotein and carbohydrate metabolism in fertile women. Ups J Med Sci 88:103-108, 1983
66. Koopersmith TB, Lobo RA: Insulin sensitivity is unaltered by the use of the Norplant subdermal implant contraceptive. Contraception 51:197-200, 1995
67. Odlind V, Lithell H, Selinus I, Vessby B: Unaltered lipoprotein and carbohydrate metabolism during treatment with contraceptive subdermal implants containing ST-1435. Ups J Med Sci 89:151-158, 1984
68. Barbosa I, Coutinho E, Athayde C, Ladipo O, Olsson SE, Ulmsten U: The effects of nomegestrol acetate subdermal implant (Uniplant) on carbohydrate metabolism, serum lipoproteins and on hepatic function in women. Contraception 52:111-114, 1995